Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefecon in Primary IgA Nephropathy (NefIgArd)
NCT03643965Phase 3Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Sep 2018
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 19
01
Overview
A Phase 3 trial of EPI-EE in IgA nephropathy (IgAN), sponsored by Calliditas Therapeutics AB. Started Sep 2018; status: completed.
02
Drugs
EPI-EE
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03643965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643965.